ClinicalTrials.Veeva

Menu

Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis

Northwell Health logo

Northwell Health

Status

Terminated

Conditions

Chronic Kidney Disease
Steroid Resistant Nephrotic Syndrome
Focal Segmental Glomerulosclerosis
Nephrotic Syndrome

Treatments

Other: Genetic Evaluation
Other: Renal Assessment
Other: Cardiovascular Assessment

Study type

Observational

Funder types

Other

Identifiers

NCT00883636
IRB# 08-163
GCRC 0245

Details and patient eligibility

About

The objective of this study is as follows:

  • Perform genetic analysis to define the prevalence of each of the known gene mutations in an unselected cohort of patients with focal segmental glomerulosclerosis (FSGS)
  • Perform a comprehensive assessment of cardiovascular status to determine the incidence of any cardiac abnormalities in patients with FSGS
  • Determine if patients with mutations in specific proteins are more likely to have cardiovascular abnormalities
  • Initiate long-term follow up in all patients to determine whether cardiac prognosis is related to any specific genetic abnormality

Full description

Nephrotic Syndrome is a frequent cause of chronic kidney disease in children. Patients who are unresponsive to treatment with corticosteroids are further categorized as having steroid resistant nephrotic syndrome (SRNS). Renal biopsy in SRNS patients often reveal the histological lesion of focal segmental glomerulosclerosis (FSGS).

Genetic research has identified mutations in specific podocyte proteins, which may lead to the development of steroid resistant nephrotic syndrome. In addition to being expressed in the fetal adult kidney, human podocin mRNA is also expressed in the fetal heart tissue. Multiple case reports have described an association between cardiac abnormalities and familial FSGS. These findings suggest that this gene may be involved in the pathogenesis of cardiac abnormalities seen in this population.

The objectives of this study is to:

  • Perform genetic analysis to define the prevalence of each of the known podocyte gene mutations in an unselected cohort of patients with FSGS
  • Perform a comprehensive assessment of cardiovascular status to determine the incidence of any cardiac abnormalities in patients with FSGS
  • Determine if patients with mutations in specific podocyte proteins are more likely to have cardiovascular abnormalities
  • Initiate long-term follow up in all patients to determine whether cardiac prognosis is related to any specific genetic abnormality

Enrollment

4 patients

Sex

All

Ages

6 months to 21 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 6 months - 21 years
  • SRNS, defined as failure to achieve remission in proteinuria after 4-6 weeks of daily steroid therapy in accord with ISKDC guidelines
  • GFR > 30 ml/min/1.73 m^2
  • Renal disease diagnosed based on kidney biopsy

Exclusion criteria

  • Secondary FSGS
  • Prior renal transplantation
  • Congenital extra-renal abnormalities
  • Significant structural cardiac abnormalities
  • pulmonary, hematologic, malignancy, or immune-related disease
  • inability to maintain adequate follow-up

Trial design

4 participants in 2 patient groups

Focal Segmental Glomerulosclerosis
Treatment:
Other: Renal Assessment
Other: Cardiovascular Assessment
Other: Genetic Evaluation
Non-Focal Segmental Glomerulosclerosis
Treatment:
Other: Renal Assessment
Other: Cardiovascular Assessment
Other: Genetic Evaluation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems